Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Key PointsCathie Wood owns Beam shares worth roughly $220 million, at the stock's current price.
Cathie Wood, CEO of Ark Investment Management, has recently added $2.8 million to her Beam Therapeutics (BEAM) holdings through Ark Genomic Revolution fund. Beam specializes in a precise gene editing technique called base editing, which allows for targeted modifications to the genetic code without causing harmful DNA breaks. This technology sets Beam apart from traditional CRISPR-Cas9 methods, which carry risks of unintended chromosomal rearrangements.
Beam's therapies are in early-stage trials, focusing on high-value diseases such as sickle cell disease (SCD) and alpha-1 antitrypsin deficiency (AATD). The company's lead therapy, ristoglogene autogetemcel, is an investigational ex vivo cell therapy that modifies a patient's own hematopoietic stem cells to produce fetal hemoglobin and suppress sickling.
Beam maintains a relatively strong balance sheet, with $1.15 billion in cash as of Q2, supporting operations through mid-2029. Although the company reported a $2.09 loss per share in its first six months, revenue grew by 50.5% year-over-year. As Beam's programs progress through phase 1/2 clinical trials, the next 12 to 18 months will provide crucial regulatory and clinical data readouts.
A positive outcome could significantly boost the stock price, making Beam Therapeutics an attractive investment for those willing to manage potential volatility and risk.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
